MedTrace Logo

Smoking Cessation Assistance With LIBERTAL, A Phospholipid Mixture

NCT00317213 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2008-04-14

No results posted yet for this study

Summary

It has been shown in rodent models that chronic substance abuse is associated with a rigidification of cell membrane fluidity due to a change in the membrane cholesterol/phospholipids ratio. Upon substance withdrawal the membrane undergoes reequilibration of this ratio, a process resulting both in an acute and a prolonged severe withdrawal syndrome. MBM has developed a patented,phosphatidic acid-enriched phospholipid platform ("LIBERTAL"), which is supposed to facilitate the membrane fluidity recovery. The company has focused on nicotine withdrawal in smoking cessation,as primary target.

Conditions

  • Smoking

Interventions

DRUG

LIBERTAL- a phospholipid mixture

Sponsors & Collaborators

  • Modus Biological Membranes, Ltd.

    collaborator INDUSTRY

  • Kaplan Medical Center

    lead OTHER

Principal Investigators

  • Zeev T. Handzel, M.D. · Kaplan Medical Center

  • Avner Shenfeld, Ph.D, · Modus Biological Membranes

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-02-28
Completion
2002-07-31

Countries

  • Israel

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00317213 on ClinicalTrials.gov